Referring to Vogue and InStyle, she said "The ads in those magazines are as interesting as the photo shoots and the articles." She added, for good measure, "I miss the ads when they are not there. I feel less fulfilled."
This says, I suspect, something about her own reading habits. Mayer, in the picture accompanying the interview, is wearing Oscar de la Renta, a favorite of Vogue and its editor, Anna Wintour. (Vogue lavishly profiled Mayer in August wearing Michael Kors.) But it also says something about the nature of advertising, a business that is key to the company she runs, but one that she does not seem to know all that much about.
10 Best Integrated Utility Stocks To Invest In Right Now: Vanguard Growth Index Fund (VUG)
Vanguard Growth ETF (the Fund), formerly known as Vanguard Growth VIPERs, is an exchange-traded share class of Vanguard Growth Index Fund. The Fund seeks to track the investment performance of the Morgan Stanley Capital International (MSCI) US Prime Market Growth Index (the Index). The Index is designed to represent the large-cap growth segment of the United States equity market.
The Index represents the growth companies of the MSCI US Prime Market 750 Index. The MSCI US Prime Market 750 Index represents the universe of predominantly large-capitalization companies in the United States equity market. The Fund employs a passively managed, full-replication strategy in seeking to track the Index. The Fund invests in all of the Index stocks, holding each stock in approximately the same proportion as its weighting in the Index.
Advisors' Opinion:- [By Mark Salzinger]
Our preferred large-cap growth ETF is Vanguard Growth (VUG), which we feature in all four of our core Best Buys model portfolios. It has fairly broad coverage of growth stocks, with more than 350 holdings. Its expense ratio is a miniscule 0.10%.
10 Best Up And Coming Stocks To Invest In 2014: Bank of Nova Scotia (BNS)
The Bank of Nova Scotia (the Bank) is a diversified financial institution. As of October 31, 2011, the Bank offered a range of products and services, including retail, commercial, corporate and investment banking to more than 18.6 million customers in more than 50 countries around the world. The Bank has four business lines: Canadian Banking, International Banking, Scotia Capital and Global Wealth Management. In January 2012, the Company closed its acquisition of 51% of Banco Colpatria. In April 2012, the Company through Scotia Capital Inc. acquired Howard Weil Incorporated. In April 2013, Bank of Nova Scotia acquired a 50% interest in Administradora de Fondos de Pensiones Horizonte SA. Advisors' Opinion:- [By Alex Barinka]
Bank of Nova Scotia (BNS) fell 1.7 percent to C$57.71. Canada�� third-largest lender by assets said net income for the period fell 14 percent from a year earlier when the bank had a one-time gain. Earnings from its global banking and markets business slipped 3 percent in the latest quarter.
- [By Tim Gallagher]
Mosaic (MOS), Agrium (AGU), Intrepid Potash (IPI) and CF Industries (CF) have been moving and trading hand-in-hand, with AGU, BHP and Rentech Nitrogen Partners LP (RNF) trading the best, losing the least and rebounding the most since July 30th. IPI has sold off a lot more in the post-news period, as would be expected from a smaller, less established company with mine projects still in development. BHP Billiton Ltd. (BHP) announced plans to proceed with its Jansen Mine Project in Saskatchewan, Canada, potentially tapping the largest and longest-lasting supply in the world known at this time. Scotiabank (BNS) recently commented on Jansen, stating that the added supply "could add the equivalent of 18%-20% of the potash market over recent years." Nearly all of the companies mentioned have had a pretty predictable mix of upgrades and downgrades. That's what makes a market.
- [By Will Ashworth]
TD Rating: 7.5
Bank of Nova Scotia (BNS)Dividend Yield: 3.9%
The last of the major Canadian banks is Bank of Nova Scotia (BNS). Not known for its Canadian retail banking, its biggest calling cards are its businesses outside of Canada in Latin America and Asia. Analysts expect it to deliver a 9.1% increase in adjusted net income in the fourth quarter to C$1.6 billion, 47% of which will come from outside of Canada.
- [By Mike Deane]
Before the opening bell today, The Bank of Nova Scotia (BNS) announced its fourth quarter earnings, posting higher net income than last year’s same quarter.�
BNS Earnings in Brief
-BNS reported Q4 net income of $1.7 billion, up 12% from last year’s Q4 net income of $1.52 billion.
-Adjusted diluted EPS came in at $1.31, up from last year’s Q4 EPS of $1.20.
-The company’s EPS matched analysts’ EPS estimates.
-For the full year, BNS reported net income of $6.7 billion, and EPS per diluted share of $5.15.CEO Commentary
Brian Porter, Scotiabank President and CEO, had the following to say about the company’s fiscal year: “Scotiabank experienced another year of solid performance with underlying earnings growing 15%. The Bank’s enterprise strategy and diversified business model continue to differentiate us from our competitors in Canada and internationally and once again have enabled us to deliver strong results.”
Dividend Declared
BNS declared a quarterly dividend of 62 cents, which will be paid on January 29, 2014 to all shareholders of record on January 7, 2014. The stock goes ex-dividend on January 3. BNS most recently its dividend in October this year, where the dividend increased from 60 to 62 cents.
Stock Performance
BNS stock was inactive in pre-market trading. YTD, the stock is up just 2.06%, lagging the broader market.
10 Best Up And Coming Stocks To Invest In 2014: Prosensa Holding NV (RNA)
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company�� primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington�� disease. The Company�� clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company�� platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
DMD is a rare, severe muscle wasting disease that occurs in up to 1 in 3,500 male births. It is commonly diagnosed between the ages of three to five, when boys begin to show signs of impaired motor development. PRO044, the Company�� product candidate, addresses a separate sub-population of DMD patients. The Company developed PRO044 using its exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.
Advisors' Opinion:- [By John Udovich]
Recent news surrounding small cap biotech stocks like�Xencor Inc (NASDAQ: XNCR), Prosensa Holding NV (NASDAQ: RNA),�Puma Biotechnology Inc (NYSE: PBYI),�Geron Corporation (NASDAQ: GERN)
and TNI BioTech Inc (OTCQB: TNIB) show that while the sector and appetite for biotech�IPOs may have cooled, lottery tickets can still be found or occur in the sector. Just consider the following recent news or trends:
10 Best Up And Coming Stocks To Invest In 2014: Perceptron Inc.(PRCP)
Perceptron, Inc. develops, produces, and sells non-contact measurement and inspection solutions in the Americas, Europe, and Asia. It offers AutoGauge systems that are used in the assembly and fabrication plants of automotive manufacturers; AutoGauge Plus, which offers freeform surface scanning and discrete feature measurement in one solution; AutoFit systems that are used in automotive manufacturing plants to contain, correct, and control the fit of exterior body panels; AutoScan systems, which provide a non-contact method of gathering data for the analysis of the surface contour of a part or product; and AutoGuide systems to calculate the difference between theoretical and actual relationships of a robot and the part being assembled, and send compensation data in six degrees of freedom to the robot. The company also offers ScanWorks, a hardware/software component set that allows customers to add digitizing capabilities to their machines or systems; ScanWorks xyz, a 3D sc anning solution designed for retrofitting 3-axis machines; ToolKit, a software solution for CMM manufacturers, system integrators, and application software developers; WheelWorks software and sensors that offer a non-contact method of measuring wheel position for use in automated or manual wheel alignment machines in automotive assembly plants; and Multi-line Sensors for use in automotive assembly plant wheel alignment systems. In addition, it manufactures visual inspection devices and accessories for the mechanical market; plumbing diagnostic equipment, meter imager systems, line detector accessories, and handheld inspection devices for the plumbing market; optical inspection devices for the construction and DIY market; and imaging solutions for the electrical market, as well as offers value-added services, including training, field services, launch support, consulting, maintenance agreements, repairs, and software tools. The company was founded in 1981 and is headquartered in Plymouth, Michigan.
Advisors' Opinion:- [By Garrett Cook]
In trading on Tuesday, industrials shares were relative leaders, up on the day by about 0.26 percent. Top gainers in the sector included Perceptron (NASDAQ: PRCP), up 10.9 percent, China Ming Yang Wind Power Group (NYSE: MY), up 4.8 percent.
10 Best Up And Coming Stocks To Invest In 2014: Southern Cross Exploration NL (SXX)
Southern Cross Exploration NL is an Australia-based company engaged in the investment in the Bigrlyi Uranium Joint Venture, on which pre-development investigations and further drilling were carried out; exploration for gold and minerals, reviews of opportunities for participation in and/or acquisition of mineral exploration and mining ventures, and examination of projects in respect of different commodities, share investments, loans and other securities. The Bigrlyi project is located in the Ngalia Basin, northwest of Alice Springs, in the Northern Territory. The Company's interest in the Bigrlyi Uranium Joint Venture is one of its assets, in joint venture with two multi-billion dollar companies, CGNPC - via the Operator, Energy Metals Ltd (EME) - and Paladin Energy Ltd (PDN). Advisors' Opinion:- [By idahansen]
Due to the impact of The Great Recession, stocks in the agricultural sector such as Caterpillar (NYSE: CAT), The Mosiac Company (NYSE: MOS), and Potash of Saskatchewan (NYSE: POT) are trading well below highs. The exchange traded fund for the industry, DBA Power Shares, (NYSE: DBA), is down more than 17% for the last year. Despite this bearish trend, legendary investors such as Warren Buffett, George Soros, and Jim Rogers are very positive for the agriculture group. With the long term bullish outlook for the sector from the greatest investors in history, small cap stocks active in the fertilizer sector such as Sirius Minerals (LSE: SXX) and Americas Petrogas (TSX: BOE) are especially attractive.
10 Best Up And Coming Stocks To Invest In 2014: Biogen Idec Inc(BIIB)
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer's disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Advisors' Opinion:- [By Ben Levisohn]
With stocks selling off and biotech giants like Gilead Sciences (GILD) and Biogen Idec (BIIB) falling, Regeneron (REGN) picked a heck of a day to deliver good news.
10 Best Up And Coming Stocks To Invest In 2014: Deutz AG (DEZ)
DEUTZ AG is a Germany-based manufacturer of diesel engines. The Company produces engines with outputs of between 19 kilowatts (kW) and 520 kW for on-road as well as non-road applications. Its activities cover development, design, production, sales and services for diesel engines that are cooled by water, oil or air. DEUTZ AG divides its activities into two segments: DEUTZ Compact Engines and DEUTZ Customized Solutions. DEUTZ Customized Solutions segment focuses on air-cooled engines and large liquid-cooled engines with capacities of more than eight liters. The segment DEUTZ Compact Engines comprises liquid-cooled engines with capacities of less than four liters as well as engines with capacities of four to eight liters. The Company is the executive and operating company within the DEUTZ Group. It has a global reach with its production sites, ten distribution companies, nine sales offices, as well as over 800 distribution and service partners in more than 130 countries worldwide. Advisors' Opinion:- [By Jonathan Morgan]
RWE AG (RWE) jumped 6.4 percent, leading a gauge of utilities higher. Deutz AG (DEZ) plunged the most in more than two years after an investor sold a 8.4 percent stake in the manufacturer of diesel engines. ProSiebenSat.1 Media AG (PSM) dropped 1.1 percent after Telegraaf Media Groep NV sold its stake in the company.
No comments:
Post a Comment